Biomea Fusion Inc (BMEA)vsModerna Inc (MRNA)
BMEA
Biomea Fusion Inc
$1.74
+2.35%
HEALTHCARE · Cap: $126.12M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
BMEA leads profitability with a 0.0% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).
BMEA
Avoid19
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BMEA.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Trading at 10.2x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BMEA
The strongest argument for BMEA centers on Debt/Equity.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : BMEA
The primary concerns for BMEA are Price/Book, Revenue Growth, EPS Growth.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
BMEA profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
BMEA generates stronger free cash flow (-10M), providing more financial flexibility.
Bottom Line
MRNA scores higher overall (21/100 vs 19/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biomea Fusion Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Biomea Fusion, Inc., a biopharmaceutical company, is focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company is headquartered in Redwood City, California.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?